Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

NCT03656510 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
246
Enrollment
INDUSTRY
Sponsor class

Stopped Janssen made the strategic decision to discontinue the CROCuS study. This decision is not based on any safety concerns.

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC